1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Venus Remedies Limited

Venus Remedies Limited

VENUSREM.BO
Venus Remedies LimitedIN flagBombay Stock Exchange
1,746.90
INR
+82.25
- -
23.46BMarket Cap
Venus Remedies Limited
VENUSREM.BO
(Bombay Stock Exchange)

Recent

price

1,746.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
397.72
444.81
480.11
476.88
405.02
361.5
345.21
299.38
257.23
274.94
444.11
453.66
413.99
442.47
488.33
- -
571.79
Revenue per Share
50.63
51.22
58.8
57.17
4.51
1.48
-14.88
-24.87
-23.16
-8.1
50.04
30.86
19.87
21.31
33.89
- -
76.91
Basic EPS, GAAP
40.9
45.34
-53.25
-37.37
0.33
-3.12
11.17
25.27
28.69
56.57
106.82
31.15
21.55
17.78
51.14
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
10
95.57
115.47
131.37
133.63
96.94
82.81
52.43
29.33
20.85
70.81
98.05
116.33
137.5
171.01
- -
10
Book Value per Share
118.82
140.38
179.31
209.63
190.03
162.38
170.28
146.93
133.32
176.66
245.96
267.14
285.1
300.99
341.24
- -
426.25
Tangible Book Value per Share
9
9
10
11
11
11
11
12
12
12
12
13
13
13
13
- -
13
Basic Weighted Avg Shares
3,631
4,088
4,679
5,363
4,635
4,149
3,963
3,695
3,174
3,393
5,481
5,986
5,534
5,914
6,529
7,696
7,643
Sales/Revenue/Turnover
19.69
19.12
18.62
17.7
9.36
9.54
2.69
1.53
-0.46
2.6
3.38
4.77
5.01
5.61
7.05
15.8
15.22
Operating Margin (%)
191
113
331
402
460
416
403
338
340
320
353
335
323
264
225
257
257
Depreciation Expense
462
471
573
643
52
17
-171
-307
-286
-100
618
407
266
285
453
1,028
1,028
Net Income, GAAP
12.19
7.42
8.8
6.92
- -
51.56
- -
- -
- -
- -
- -
- -
29.96
36.18
36.91
23.01
23.38
Effective Tax Rate (%)
12.73
11.52
12.25
11.99
1.11
0.41
-4.31
-8.31
-9
-2.95
11.27
6.8
4.8
4.82
6.94
13.35
13.45
Profit Margin (%)
138
151
343
611
704
839
626
299
18
694
1,366
1,853
2,403
2,801
3,154
2,334
2,334
Working Capital
880
991
1,291
1,400
2,023
1,910
1,618
1,374
1,160
721
468
387
387
387
- -
110
110
LT Debt
2,369
3,073
3,791
4,616
4,567
3,997
3,887
3,619
3,325
3,234
4,003
4,404
4,603
4,876
5,609
6,638
6,638
Total Equity
19.45
16.97
13.49
12.62
- -
2.54
- -
- -
- -
- -
- -
- -
3.94
4.1
5.32
15.12
14.39
Return on Invested Capital (%)
49.24
34.45
22.27
21.35
- -
3.8
- -
- -
- -
- -
- -
- -
14.4
13.5
19.92
80.29
80.3
Return on Capital (%)
524.58
97.1
57.2
49.4
3.43
1.29
-16.56
-38.42
-56.64
-32.29
109.2
37.57
18.65
16.79
21.97
84.94
84.96
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
26
- -
14
LT Borrowings
- -
- -
- -
LT Finance Leases
117
- -
110
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
- -
13
Market Capitalization
5,881
10,253
11,036

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
4,857
- -
3,952
Cash, Cash Equivalents & STI
2,362
- -
1,039
Accounts Receivable, Net
966
- -
1,033
Inventories
1,067
- -
1,294
Total Current Liabilities
1,430
- -
1,618
Payables & Accruals
- -
- -
- -
ST Debt
26
- -
14
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.71%
10.77%
18.33%
Free Cash Flow
2.89%
28.82%
72.69%
Net Income, GAAP
-169.11%
24.86%
126.84%
Sales/Revenue/Turnover
7.99%
7.36%
17.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
952
1,677
1,434
1,852
5,914
2025
1,086
1,701
1,765
1,977
6,529
2026
1,319
1,928
1,803
2,594
7,696

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.88
7.44
5.13
- -
21.31
2025
0.92
2.63
14.66
15.71
33.89
2026
7.18
15.06
19.14
35.53
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
PharmaEssentia Corporation (6446.TW)
Radient Technologies Inc. (RTI.V)
Solasia Pharma K.K. (4597.T)
Boiron S.A. (BOIRF)
StateHouse Holdings Inc. (STHZF)
China Health Industries Holdings, Inc. (CHHE)
Business
Venus Remedies Limited (VENUSREM.BO) is an Indian research-driven pharmaceutical company specializing in the development, manufacturing, and marketing of innovative injectable drugs and formulations targeting critical therapeutic segments including anti-infectives, oncology, neurology, cardiovascular, pain management, gastroenterology, and antimicrobial resistance solutions; its core products encompass antibiotics such as Meropenem, Ceftriaxone, and Tobacef, oncology injectables like Gemcitabine and Topotecan, analgesics, anticoagulants, antiemetics, antivirals, and specialized offerings like the Nanosponge technology-based Trois emulsion for pain relief, alongside brands including Lastinem, Linomax, Megaparin, and Venorab. Founded in 1989 and headquartered in Panchkula, India, with manufacturing facilities across India and a European subsidiary Venus Pharma GmbH in Germany, the company operates globally across more than 20 countries in regions including Europe, the Middle East, Southeast Asia, Latin America, and Africa, serving hospitals, governments, and distributors through a focus on high-quality sterile injectables and research-backed innovations. Recent developments include a strategic licensing partnership with UK-based Infex Therapeutics for the exclusive rights to develop and commercialize MET-X, a first-in-class metallo-beta-lactamase inhibitor targeting drug-resistant Gram-negative infections in India; regulatory approvals for lung cancer drugs expanding its Southeast Asian footprint; renewed GMP certification from Ukraine's SMDC affirming manufacturing excellence; joining the United Nations Global Compact to advance sustainable business practices; and achieving over 138 marketing authorizations in Europe via Venus Pharma GmbH as of 2024, alongside positive quarterly financial results driving stock performance.